Meeting
2021 ASCO Annual Meeting
ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Sumit Kumar Subudhi
The University of Texas MD Anderson Cancer Center, Houston, TX
Sumit Kumar Subudhi , Johanna C. Bendell , Michael Anthony Carducci , Lisa M. Kopp , Jennifer Scott , Michele M Grady , Olivia Gardner , David R Wise
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04381832
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5039)
DOI
10.1200/JCO.2021.39.15_suppl.5039
Abstract #
5039
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer.
First Author: David R. Wise
Poster
2012 Genitourinary Cancers Symposium
Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
First Author: Ignacio Gil-Bazo
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Teresa Alonso Gordoa
Poster
2021 Genitourinary Cancers Symposium
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.
First Author: Adam Kessel